

1 **Technical report: A comprehensive** 2 **comparison between different** 3 **quantification versions of Nightingale** 4 **Health's ¹H-NMR metabolomics platform**

5 D. Bizzarri^{1,2,3}, M.J.T. Reinders^{2,3}, M. Beekman¹, BBMRI-NL⁵, P.E. Slagboom^{1,4}, and
6 E.B. van den Akker^{1,2,3,#}

7 ¹Molecular Epidemiology, LUMC, Leiden, The Netherlands

8 ²Leiden Computational Biology Center, LUMC, Leiden, The Netherlands

9 ³Delft Bioinformatics Lab, TU Delft, Delft, The Netherlands

10 ⁴Max Planck Institute for the Biology of Ageing, Cologne, Germany

11 ⁵BBMRI-NL: <https://www.bbMRI.nl>; see Consortium Banner Supplement S1

12 **Material & correspondence (#)**

13
14 **Erik B. van den Akker, PhD; Leiden Computational Biology Center, Leiden University Medical Center, Leiden, The**
15 **Netherlands; Einthovenweg 20, 2333 ZC, Leiden, The Netherlands; Tel: +31 (0)71 526 85 57; Fax: +31 (0)71 526 82 80; E-mail:**
16 **e.b.van.den.akk@lumc.nl; website: <http://www.lcbc.nl>**

17 **Abstract**

18 ¹H-NMR metabolomics data is increasingly used to track various aspects of health and disease.
19 With the availability of larger data resources and continuously improving learning algorithms
20 Nightingale Health has recently updated the quantification and calibration strategy of their
21 platform to further align their reported analytes with clinical standards. Such updates, however,
22 might influence backward replicability and could hamper comparison of repeated measures in
23 longitudinal studies. Based on data of the BBMRI.nl consortium (>25.000 samples across 28
24 studies), we compared Nightingale data, as originally released in 2014 and 2016, with a re-
25 quantified version of this data released in 2020, of which both versions were based on the same
26 original NMR spectra. Apart from 2 discontinued, and 23 newly defined analytes, we overall
27 observe a high concordance between quantification versions, with 73 out of 222 (33%) showing a
28 mean correlation > 0.9 across the 28 Dutch cohorts. Nevertheless, five metabolites consistently
29 showed relatively low correlations (R<0.7) between platform versions, namely acetoacetate

30 (*acace*), LDL particle size (*ldl_d*), saturated fatty acids percentage (*sfa_fa*), S-HDL-C (*s_hdl_c*)
31 and sphingomyelins (*sm*). Previously trained multi-analyte scores, such as our previously
32 published health predictors *MetaboAge* or *MetaboHealth*, might be particularly sensitive to
33 platform changes. Whereas the *MetaboHealth* score replicated well between platform versions, the
34 *MetaboAge* score indeed had to be retrained due to discontinued metabolites. Notably, both scores
35 projected on the 2020 re-quantified data did recapitulate the original mortality associations
36 observed in the previous version of the data. Concluding, we urge caution when utilizing data from
37 different quantification versions to avoid mixing analytes capturing different underlying aspects
38 of the NMR spectra, having different units, or simply being discontinued.

39 **Introduction**

40 Targeted ¹H-NMR Metabolomics has rapidly gained popularity as a cost-effective and
41 comprehensive method to perform metabolic profiling and risk prediction in large epidemiological
42 studies. Various of such metabolomics-based age predictors were constructed, for example
43 *MetaboAge*, an indicator of several future cardiovascular diseases [1] and *MetaboHealth* that
44 predicts multiple health conditions and all-cause mortality [2]. Thus far, targeted ¹H-NMR
45 Metabolomics has shown promise to predict COVID hospitalization [3], various disease outcomes
46 [4,5], and a plethora of conventional clinical risk variables [6].

47 Targeted ¹H-NMR approaches focus on the analysis of a limited and pre-defined set of
48 analytes, whose associated peaks consistently appear at relatively fixed positions in the overall
49 NMR spectrum of a specific biomaterial and can therefore be robustly quantified. Each of the
50 associated peaks are quantified according to standardized rules and then transformed into absolute
51 quantities with the aid of reference compounds [7]. While each change in the assayed biomaterials
52 or isolation protocols would necessitate a considerable effort to re-calibrate a ¹H-NMR-based

53 quantification setup, a rigid standardization of both the input material and the laboratory routines
54 would allow for a cost-effective and metabolome profiling on an epidemiological scale.

55 Nightingale Health Plc is a major commercial supplier of targeted ¹H-NMR metabolomics
56 data with bench-to-data solutions for human serum, plasma, or urine, for a limited number of
57 metabolic markers. Large consortia like BBMRI.NL [1], FINSK/THL [5], COMETS [8], and
58 more recently UK-Biobank [3] have set out to enrich their population studies with ¹H-NMR
59 metabolomics profiling and to date have accumulated data in respectively ~35.000, ~40.000,
60 ~46.000, and ~300.000 samples. Sample handling and processing inevitably varies during and
61 between such large efforts and may introduce variation in the data that could potentially impede
62 replication efforts. In parallel with their metabolomics profiling efforts in UK-Biobank,
63 Nightingale Health updated the way their analytes are quantified to further improve the calibration
64 of 37 of their analytes with clinically measured counterparts. While such updates constitute a
65 further optimization of this biomarker platform, it may also introduce systematic changes with
66 respect to previously assayed studies [9].

67 Here, we set out to quantify to which extent the most recent updates of the quantification
68 procedure by Nightingale affected the reported analytes, and to what extent this could influence
69 replication of previous findings. We investigated the metabolic-specific correlations in ~220
70 features, quantified by Nightingale Health, available for the *same* samples across three different
71 platform versions (2014, 2016 and 2020). We found that, while many analytes present a high
72 degree of correlation between versions, a number of analytes present a moderate to low correlation.
73 In addition, we demonstrate that the effect on multi-analyte scores may differ, and thus ideally
74 would require their renewed validation for each platform update. For example, the *MetaboHealth*
75 score exhibits similar associations with time to death, whereas the metabolomics-based age

76 predictor (*MetaboAge*) could no longer be readily applied due to use of discontinued metabolites
77 yet could be successfully retrained on the new platform version and showed similar associations
78 with disease outcomes.

79 **Results**

80 All comparisons are done on data gathered within the BBMRI.NL consortium (~35,000 samples
81 in 28 cohorts, Methods Table 1). Samples were assayed using the Nightingale Health platform in
82 multiple waves of data generation, as indicated with their respective years: 2014 and 2016. After
83 the complete platform update by Nightingale of 2020, BBMRI.NL decided to re-quantify their
84 dataset completely to have metabolomics features comparable to other consortia. It is important to
85 stress that re-quantification consisted of a novel (computational) analyte quantification of the
86 original assays performed in 2014 and 2016; i.e., no new samples were assayed.

87

88 **An overview of changes in measured metabolic features**

89 With respect to marker availability, there are new and discontinued reported entities. Notably, the
90 latest version of the platform (2020 version) includes 37 biomarkers which have been CE-approved
91 for diagnostic purposes, i.e., ‘clinically validated’, making the Nightingale platform now not only
92 interesting for epidemiological research, but also suited for use in the clinic [10]. In addition, 25
93 new variables were added to the pool of metabolic markers now also readily measurable in EDTA
94 plasma (Supplementary Materials). Moreover, the analyte pyruvate (pyr) is featured on the
95 platform again, after being discontinued in 2016. Conversely, analytes showing insufficient
96 replicability were discontinued, either already in the 2016 version (*dag*, *dagtg*, *fallen*, *cla*, *cla_fa*),
97 or from 2020 onward (*hdl2_c* and *hdl3_c*), thus posing potential backward compatibility issues.

98 Looking more closely to the data, we also note some more subtle changes that nevertheless
99 are helpful to highlight. Compared to older platform versions, the proportion of problematic values
100 decreased in the re-quantified version of the platform, i.e., there are less values that failed to be
101 detected (NaNs), were reported as zero, or were considered outliers (**Figure S1**). In addition, we

102 observe that some markers were reported using different units between, and occasionally within,
103 platform versions. For instance, albumin (alb) changed unit from [signal area] in 2014 to [g/L] in
104 2020. Particularly interesting are the different ranges of creatinine in the re-quantified
105 measurements (2020 version), which in our case seems to depend on whether the first Nightingale
106 metabolomics quantification was done either in 2014 or in 2016, with reported units in mmol/L
107 and $\mu\text{mol/L}$ respectively (Figure S2). These changes, if unnoticed, can impair replication of the
108 results and application of multi-variate models.

109

110 **Correlation analyses of metabolomics measurements between** 111 **platform versions**

112 First, we evaluated the correlation for each homonymous metabolic measurement across the
113 different Nightingale platform versions within the Leiden Longevity study (LLS); a two-
114 generation cohort containing highly aged individuals (LLS-SIBS) and their offspring with the
115 relative partners (LLS-PAROFFS), with repeated measures over different time-points (IOP1, 2
116 and 3) (detailed description in *Material and Methods*). Considering same samples of LLS-
117 PAROFFS IOP1, measured the first time in 2014 and re-quantified in 2020 (Figure 1A), we
118 observed that 36 out of the 65 homonymous non-derived analytes (55%), showed a correlation
119 higher than 0.9, with one having a perfect correlation (*glucose*). 24 had a medium correlation (0.7
120 $\leq R < 0.9$), and only five analytes had a correlation lower than 0.7 (*acace*, *ldl_d*, *sfa_fa*, *s_hdl_c*
121 and *sm*). Some analytes showed a shift in mean values, presumably as a result of a recalibration
122 step, as reflected by a change in levels, e.g. *ldl_d*: first wave [22.99÷25.5 nm] vs. re-quantified
123 [23.4÷24.09 nm], or in units, e.g. *alb*: first wave [0.06÷0.14 signal area] vs. re-quantified
124 [25.6÷62.78 g/l]. Furthermore, also 54 out of the remaining 169 analytes, mostly containing
125 derived measures, showed lower correlations ($R < 0.7$) (Figure S4).

126




Figure 1: Evaluation of the metabolic markers before and after re-quantification in LLS-PAROFFS IOP1: [A] Spearman’s correlations of the homonymous analytes measured in the first wave (2014) with their re-quantified version (2020).

127 When computing the same correlation analyses comparing LLS_PAROFFS IOP1 (2014 data) with
 128 another cohort measured in the first wave, LLS-SIBS (2014 data), or with data of the same cohort
 129 of the second wave LLS_PAROFFS IOP2 (2016 data), we observe highly similar trends (Fig2A
 130 and S5A). While the majority of analytes show consistently high correlations with their re-
 131 quantified counterpart across waves and cohorts, we do observe some notable exceptions. Analytes
 132 with a low calibration correlation ($R < 0.7$) in the first data wave (either LLS_PAROFFS, or LLS-
 133 SIBS 2014 data) seem to show improvement in the second wave data (either LLS_PAROFFS,
 134 2016 data), except for *ldl_d*. Considering that we find similar results also in LLS-PAROFFS IOP3
 135 (Figure S5C-D), a second round of repeated measures quantified with the Nightingale platform
 136 2016, we concluded that this latter platform version is more similar to the re-quantified data as
 137 compared to 2014 version.

138

139 To investigate how the correlations of metabolomic features between the different Nightingale
 140 platform version behave over different cohorts, we examined these on the whole BBMRI.NL

141 dataset comprising 28 cohorts (**Figure 3**). Observed correlations vary between -0.5 (generally for
142 derived analytes, such as ratios or percentages) and perfect positive correlation (*glucose*). The
143 lower correlations were not due to a lower variance in the markers (Figure S5). Even though there
144 are some cohorts that show generally lower correlations for all the analytes (e.g., BIOMARCS, or
145 STEMI-GIPS), the other cohorts show consistent correlations for the different analytes. 73
146 analytes had a mean correlation above 0.9 across all BBMRI.NL biobanks (**Figure S6C, Table 5**).
147 33 and 8 of these markers overlap with the 65 (51%) and 14 (57%) analytes that were used to
148 construct the *MetaboAge* and *MetaboHealth* score respectively (Figure S6D).





Figure 2: Comparisons of the correlations of the metabolites before and after re-quantification in different subgroups or platform versions: Each point of the scatterplots indicate the correlations of each metabolic markers before and after the re-quantifications in [A] LLS-PAROFFS IOP1 (x axis, first measured in 2014) and LLS-SIBS (y axis, first measured in 2014); and [B] LLS-PAROFFS IOP1 (x axis, quantification version 2014) with LLS-PAROFFS IOP2 (y axis, quantification version 2016). Metabolic markers were tagged if they show differences in correlations.



149
150
151
152
153
154


Figure 3: Correlations of all the metabolomics features before and after re-quantification in all the BBMRI.NL cohorts in data 2014 vs data 2020: Each dot represents the correlation of a metabolomic feature with itself, colored based on the cohorts included in BBMRI.NL. Dots of the same cohort are connected with a line to highlight outlier patterns. A horizontal dotted line indicates a correlation of 0.9.

155 **The clinically validated biomarkers show similar correlation, but**
156 **improved calibration with respect to previous quantification**

157 The latest Nightingale metabolomics platform contains 37 analytes approved by the European
158 community for diagnostics [10]. This is particularly interesting for Consortia like BBMRI.NL, as
159 it allows for an efficient quantification of various routinely assessed clinical biomarkers in one
160 single platform. For this purpose, we evaluated to what extent previously measured clinical
161 variables within BBMRI.NL align with their corresponding analytes on the Nightingale platform.
162 Four of the 37 clinical biomarkers (HDL-cholesterol, LDL-cholesterol, triglycerides, and total
163 cholesterol) were available in 13 of the 28 cohorts (14,995 samples, Figure 4) and showed a
164 medium to high correlation in most of the cohorts, apart for BIOMARCS, PROSPER, and
165 UCORBIO [mean $R= 0.6$]. While different Nightingale versions generally showed very similar
166 correlations with their clinical chemistry counterparts, notable differences are observed when
167 considering the Median Absolute Distance (MAD). For the 2020 version, we observe an improved
168 concordance between clinically measured biomarkers and their Nightingale counterpart,
169 particularly for LDL-cholesterol and total cholesterol.

A


Correlations of the clinically validated metabolites in BBMRI.NL



170
171

B

MAD of the clinically validated metabolites in BBMRI.NL



172
173
174
175
176
177
178
179
180

Figure 4: Correlations of Nightingale metabolomics markers, measured in 2014 and 202, with the clinically measured values in BBMRI.NL: Bar-plots of the [A] spearman's correlations and [B] the Median Absolute Distance (MAD) of the *hdl cholesterol*, *ldl cholesterol* (calculated with the Friedewald equation), total cholesterol and triglycerides calculated with clinical chemistry, with their corresponding values in the Nightingale assay (*hdl_c*, *ldl_c/clinical_ldl_c*, *serum_c* and *serum_tg*). The results in blue indicate the results for the 2014 platform and in red the ones for the platform of 2020. The label on the y-axis indicates the biobank, the total number of samples with available quantification and the Standard Deviation of the clinically measured metabolite.

181

182 **The *MetaboHealth* score shows a comparable association with**
183 **mortality using re-quantified data**


184 Next, we evaluated whether the platform changes affected the replication of the *MetaboHealth*
185 score [2]. The *MetaboHealth* score correlated on average ~ 0.83 between the 2014 platform and
186 the re-quantification in 2020 over all the cohorts (Figure 5A); with a maximum of 0.91 (in LLS-
187 SIBS) and a minimum of 0.72 BIOMARCS. Higher correlations for LLS-SIBS [89÷103 y.o.] and
188 PROSPER [70÷85 y.o.] might be explained by the stronger signal caused by the fact that these
189 cohorts generally include older individuals, with a high frequency of mortality or cardiovascular
190 events. Cohort-specific differences in correlations between platform versions could be explained
191 by inconsistent correlations of *acace*, *albumin*, *s_hdl_l* and *xxl_vldl_d* that have relatively high
192 coefficients in the *MetaboHealth* score (in Figure 5B). Indeed, we notice that patient cohorts such
193 as BIOMARCS, RAAK and UCORBIO do have lower correlations.

194


195 Since the *MetaboHealth* score maintained similar predictions in the platform with re-quantified
196 metabolites, we next were interested whether the re-quantified score also showed similar
197 associations with mortality. To this end, we modeled time-to-death using a Cox proportional
198 Hazards model, while adjusting for age, sex and family relation, in LLS-SIBS ($N_{\text{total}}=797$,
199 $N_{\text{events}}=791$). Both versions remained significantly associated (2014: $HR \sim 2.18$, $p=5.42 \times 10^{-28}$, and
200 2020: $HR \sim 1.98$, $p=1 \times 10^{-30}$) albeit with a slightly attenuated effect size for the 2020 platform
201 version, but a more significant association (Figure 6).

202

203



204




205

206 *Figure 5: MetaboHealth score consistency over BBMRI.NL:* [A] Bar-plot presenting the
 207 correlation of the MetaboHealth score calculated in all the BBMRI.NL biobanks with the
 208 metabolites in the data measured in 2014 or 2020; [B] Jitter-plot of the correlations of the metabolic
 209 markers used to build the MetaboHealth score calculated in data 2014 and 2020, divided per
 210 biobank. The heatmap on top shows the coefficients of each biomarker in the MetaboHealth score.

211

LLS_SIBS: Time to death associations (corrected age, sex and Family ID)




212
213 *Figure 6: MetaboHealth score associations with Time to Death associations in LLS-SIBS:*
214 Association with Time to Death of the MetaboHealth score calculated with the metabolic markers
215 quantified in 2014 (*MetaboHealth_2014*) and the metabolic markers quantified in 2020
216 (*MetaboHealth_2020*). The two Cox regression models were performed on 797 individuals with
217 791 reported deaths and corrected for age, sex and Family relationships.

218 **A retrained *MetaboAge* on re-quantified data shows similar** 219 **associations with mortality compared to the previous version of** 220 ***MetaboAge***

221 Since two essential variables (*hld2_c* and *hdl3_c*) were discontinued in the 2020 platform, the
222 original *MetaboAge* model (*MetaboAge 1.0*) could not be computed. Therefore, we decided to
223 retrain the *MetaboAge* model using the re-quantified Nightingale 2020 measurements, either using
224 a: 1) a linear model (LM), consistent with the previous *MetaboAge* model; and 2) an elastic net
225 regression (EN), regularizing the contributions of each individual metabolite. 5-Fold Cross
226 Validation, over the BBMRI.NL dataset (~20,366 samples, after quality control), showed overall
227 similar accuracies, with a slight advantage for the linear model (*MetaboAge 2.0: LM*,
228 $R^2=0.451$; EN, $R^2=0.449$, Figure S5). Correlations between the old and new versions of the models
229 over all the BBMRI.NL biobanks showed cohort-specific differences, with low correlations in the
230 RAAK cohort ($R=0.5$) and moderately to high correlations for the ERF and FUNCTGENOMICS
231 cohorts ($R=0.85$ and 0.86 , respectively) (Figure S8). Nonetheless, we observe an overall high
232 correlation between the two novel versions of the *MetaboAge* models ($R=0.99$) (Figure 7B),

233 despite that the informative metabolomics features are quite different across the three models
234 (Figure 7A). Yet the elastic net version has a slightly higher correlation with the MetaboAge
235 1.0 (LM: R= 0.82 and EN: R=0.83, Figure 7A). Nonetheless, the linear model assigns higher
236 coefficients to only few features compared to the elastic net model (Figure 7A) (MetaboAge
237 1.0 [range: -150,150], MetaboAge 2.0: LM [range: -40000, 1000000], MetaboAge 2.0:
238 EN [range: -100, 50]).

239
240 Finally, we performed a Cox-regressions analysis to predict time-to-death (corrected for age sex
241 and family relation) in the LLS-SIBS cohort ($N_{\text{total}}=806$, $N_{\text{events}}=800$) (Figure 7C). The associations
242 with mortality are quite similar (equivalently significant and moderate effect sizes) across all
243 models, but slightly higher for the MetaboAge 2.0 models (LM: HR~1.2, $p=1.69 \times 10^{-08}$ and
244 EN: HR~1.2, $p=2.39 \times 10^{-08}$, MetaboAge 1.0: HR~1.18, $p=2.89 \times 10^{-05}$).



245

246 *Figure 7: MetaboAge 2.0 evaluations:* [A] Coefficients of MetaboAge1.0 and Metaboages2.0

247 ordered in the same manner; [B] Correlation between age, MetaboAge1.0, MetaboAge2.0 linear

248 model (LM) and ElasticNET (EN); [C] Associations of time to death with the three age predictors.

249 Discussion

250 Using the BBMRI.NL biobanking consortium we evaluated the replicability across Nightingale
251 Health platform updates between 2014, 2016, and 2020 (re-quantification). We observe
252 improvements regarding the overall quantification quality, i.e.: a decrease in missingness; lower
253 numbers of values that are reported as zero; and a better concordance with clinical measurements.
254 On the other hand, there are discontinued metabolites, and changes in reported units between and
255 sometimes within quantification versions that could affect replication efforts. Some analytes
256 displayed low calibration correlations between the 2014/2016 and 2020 platform versions, with
257 the 2016 version being more similar to the re-quantified data as compared to the 2014 version.
258 Replication over the BBMRI-nl cohorts indicated similar results, however, with lower
259 concordance for some studies (e.g., BIOMARCS, or STEMI-GIPS). Nevertheless, we identified
260 a list of 73 variables more consistent between quantification versions across the BBMRI.NL data
261 set (mean $R > 0.9$). Moreover, the *MetaboHealth* score did generally replicate well between
262 platform version in the BBMRI-nl cohorts (mean $R = 0.83$, min $R = 0.72$, BIOMARCS, and max $R =$
263 0.91 , LLS-SIBS). Lower correlations were attributed to inconsistencies in some score-related
264 analytes (*acace*, *albumin*, *s_hdl_l* and *xxl_vldl_d*). Importantly, the time-to-death association of
265 the *MetaboHealth* score was not significantly affected by the platform updates. We retrained the
266 *MetaboAge* score in BBMRI-nl due to the absence of 2 analytes in the new platform version.
267 Interestingly, the retrained version of *MetaboAge* recapitulated the association with time-to-death,
268 indicating that correlations with the original *MetaboAge* model (*MetaboAge* 1.0) showed
269 moderately high concordance over all cohorts in BBMRI.NL, apart for RAAK (cor~0.5), which is
270 a relatively small cohort of atherosclerotic people. Between the 2 versions of the *MetaboAge* 2.0

271 we believe the elastic net version to be the better model as the regularization warrants for future
272 changes of the platform.

273
274 In conclusion, replication of previous findings and analysis of repeated measures is one of the
275 cornerstones of epidemiological research. Hence, we call for caution when utilizing Nightingale
276 data quantified at different time points. Moreover, is important to realize that pre-trained metabolic
277 models cannot readily be applied across different versions of the data. In these circumstances, we
278 recommend retraining of the score, or, if this is not possible, an extensive re-evaluation of the
279 models and their associations with endpoints.

280 **Acknowledgements**

281 This work was performed within the framework of the BBMRI Metabolomics Consortium funded
282 by BBMRI.NL (a research infrastructure financed by the Dutch government, NWO 184.021.007
283 and 184.033.111), by X-omics (NWO 184.034.019), VOILA (ZonMW 457001001) and Medical
284 Delta (scientific program METABODELTA: Metabolomics for clinical advances in the Medical
285 Delta). EvdA is funded by a personal grant of the Dutch Research Council (NWO; VENI:
286 09150161810095). A full list of acknowledgements for all the contributing studies can be found
287 in the Supplementary Materials (BBMRI.NL Cohort description).

288 **Contributors**

289 EbvDA, DB, MJTR, PES and MB conceived and wrote the manuscript. DB performed the
290 analyses. DB and MB verified the underlying data. EBvDA and MJTR verified and supervised the
291 analyses. All authors discussed the results and contributed to the final manuscript. All authors read
292 and approved the final version of the manuscript.

293

294 **Data and code availability**

295 The data is available upon request at <https://www.bbmri.nl/>. A presentation of the results with
296 the code to reproduce this work can be found at
297 (https://github.com/DanieleBizzarri/NightingaleMetabolomics_Requantification2020).

298 **Competing interests**

299 The authors declare that there are no competing interests.

300 **Materials and Methods**

301 **1. Dataset descriptions**

302 The Dutch Biobanking and BioMolecular resources and Research Infrastructure (BBMRI.NL)
303 is a large consortium composed of 28 Dutch cohorts, which quantified their samples with the
304 Nightingale Health platform in different time points, allowing an investigation on the platform
305 differences over the years. About 25,000 samples from 26 cohorts were quantified during the
306 first wave in 2014. A second wave of 10,000 samples was then obtained in 2016, including
307 some longitudinal time-points and 2 new cohorts. Finally, after the 2020 update of the platform,
308 the entire BBMRI.NL (35,000 samples from 28 cohorts) was re-quantified to have comparable
309 measures to other Consortia.

310

311 **A. BBMRI.NL**

312 BBMRI.NL (<https://www.bbmri.nl/>) is a Dutch Consortium which includes a total of 35,000
313 samples from the following 28 Dutch biobanks: ALPHAOMEGA, BIOMARCS, CHARM,
314 CHECK, CODAM, CSF, DMS, DZS_WF, ERF, FUNCTGENOMICS, GARP, HELIUS, HOF,
315 LIFELINES, LLS_PARTOFFS, LLS_SIBS, MRS, NESDA, PROSPER, RAAK, RS,

316 STABILITEIT, STEMI_GIPS-III, TACTICS, TOMAAT, UCORBIO, VUMC_ADC, VUNTR.
317 Complete descriptions and ethics statement of each cohort is added to the Supplementary Material.
318 **Metabolomics Dataset:** Nightingale Health performed the quantification of high throughput
319 proton Nuclear Magnetic Resonance ($^1\text{H-NMR}$) for the EDTA plasma for BBMRI.NL in separate
320 waves (**Table 1**). The first wave was performed in 2014, on a great portion of the data (~25,000
321 samples). The second wave was performed in 2016 to quantify $^1\text{H-NMR}$ metabolomics in the
322 cohorts HOF and STABILITEIT, but also to quantify follow-ups sampling from different cohorts.
323 Finally, in 2021 a re-quantification was performed almost to the entire dataset to update the
324 metabolomics measurements to the latest platform version (platform version 2020).

	N. Samples	N. Biobanks	Platform version
<i>First wave</i>	24,994	26	Version 2014
<i>Second wave</i>	9,880	10	Version 2016
<i>re-quantifications</i>	34,015	28	Version 2020

325
326 **B. The Leiden Longevity Study**
327 The Leiden Longevity Study is one of the cohort included in BBMRI.NL, which comprises a
328 first generation subgroup of long-lived parents (LLS-SIBS, age= 89 ÷ 103 years old) and a second
329 generation which includes their middle-aged offspring with the relative partner (LLS-PAROFFS
330 age median = 30 ÷ 79 years old) [11].

331 **Metabolomics Dataset:** While only one sample collection was performed on the older individuals
332 of LLS-SIBS [998 individuals], there are three time-points available for LLS-PAROFFS drawn
333 with ~3 years gap one after the other (IOP1, IOP2 and IOP3) (Table 1). The first-time point (IOP1,
334 2,313 individuals) was quantified during the first wave in 2014, while the second and third samples
335 measurements (IOP2 and IOP3, respectively 670 and 498 individuals) were included in the second
336 wave, with the platform version 2016. All the samples were then re-quantified in 2021 with the

337 rest of BBMRI.NL data. The last column of the table shows the number of common samples after
338 the quality control of the two datasets, described in the next paragraph.

LLS-PAROFFS [30-79 years old]					
	Wave	Platform version	re-quantification	Total N. samples	N. samples after quality control
IOP1	First wave	Version 2014	Version 2020	2,313	1,983
IOP2	Second wave	Version 2016	Version 2020	670	588
IOP3	Second wave	Version 2016	Version 2020	498	388
LLS-SIBS [89-103 years old]					
IOP1	First wave	Version 2014	Version 2020	998	942

339

340 **2. Comparison of the metabolomic analytes**

341 **Preprocessing:** All the three versions of the metabolomics assays were run by Nightingale
342 Health on EDTA-plasma samples handled by the BBMRI.NL cohorts. More than 220 analytes are
343 included in all nightingale platform, however we decided to mostly focus our attention on the 63
344 mutually independent analytes used to build the previous metabolomics-based models [2,6,12].
345 However, since 2 of these analytes were discontinued (hdl2_c and hdl3_c), we substituted them
346 with 4 biologically equivalent analytes, upon Nightingale's Health advice (xl_hdl_c, l_hdl_c,
347 m_hdl_c, s_hdl_c) (lists in Supplementary Materials), which are available in all datasets. We then
348 removed samples with more than 1 missing value, more than one zero and more than one outlier,
349 defined as having a concentration more than 5 standard deviations away from the mean of the
350 analyte.

351 **Analyses:** We used Spearman's correlation to measure the strength and direction of monotonic
352 associations between the analytes in the different versions of the platform. We also used a Median
353 Absolute Distance to evaluate the error of Nightingale Health's analytes to the clinically measured
354 values. The Mean absolute distance is obtained by using mean and standard deviations of the

355 clinical measures to scale all measures (both clinical and Nightingale quantifications) to have
356 comparable results.

357 **3. MetaboHealth Score**

358 **Preprocessing:** The MetaboHealth score was applied to both the datasets (the first wave and
359 the re-quantified), according to the description by Deelen et al. [2], using the R-package MiMIR
360 [13]. First, a logarithm transformation was applied to the analytes, while adding a value of 1 to all
361 analytes containing any zero. A z-scale normalization was then applied to the log-transformed
362 analytes in each cohort separately. Finally, the coefficients as indicated by Deelen et al. [2] were
363 applied to the dataset.

364 **Analyses:** Once we obtained the score, we used spearman's correlation to compare the
365 differences in MetaboHealth score before and after re-quantification. Cox proportional hazard
366 models are then used to test the associations between the two MetaboHealth scores and time to
367 death.

368 **4. MetaboAge**

369 **Preprocessing:** The quality control process used for the dataset in the first wave of measures
370 (data 2014) is discussed in details in our previous publications [6,12]. We used the same steps also
371 in the re-quantified dataset. From the above-mentioned list of 65 analytes, we decided not to
372 consider analytes with low detection rates in several cohorts (citrate and 3-hydroxybutyrate). We
373 then excluded cohorts with several problems in the 65 selected analytes. VUNTR (N=3559) has
374 high levels of missingness in pyruvate and glutamine, while CODAM (N=145) presented outliers
375 in several metabolic features. We also removed samples with 1 or more missing value (65
376 samples), one or more zeroes per sample (1 sample) and one or more concentration more than 5
377 times the standard deviations away from the general mean of the feature (644 samples). The

378 remaining 265 missing values (0.021% of the remaining values) were imputed using nipals (in the
379 R package `pcaMethods`). The final dataset, comprising 20,366 samples and 63 analytes, was z-
380 scaled to have comparable concentrations across all features.

381 **Analyses:** Due to discontinued analytes, we had to retrain the models and we decided to train
382 2 different types of models: a linear regression model, to maintain the model as close as possible
383 to the previous version, and an ElasticNET regression, which avoids overfitting thanks to a
384 regularization technique. To train and evaluate both models we employed a 5-Fold Cross
385 Validation scheme. During the training of the ElasticNET model we fixed the mixing parameter
386 α to 0.5 and optimized the shrinkage parameter λ (like it was done in previous papers [6,14,15]).
387 As for the MetaboHealth, we then used spearman's correlations to compare the different models
388 and Cox proportional hazard models to investigate the associations with time to death.

389 References

- 390 [1] van den Akker Erik B., Trompet Stella, Barkey Wolf Jurriaan J.H., Beekman Marian,
391 Suchiman H. Eka D., Deelen Joris, et al. Metabolic Age Based on the BBMRI-NL 1H-NMR
392 Metabolomics Repository as Biomarker of Age-related Disease. *Circulation: Genomic and*
393 *Precision Medicine* 2020;13:541–7. <https://doi.org/10.1161/CIRCGEN.119.002610>.
394 [2] Deelen J, Kettunen J, Fischer K, van der Spek A, Trompet S, Kastenmüller G, et al. A
395 metabolic profile of all-cause mortality risk identified in an observational study of 44,168
396 individuals. *Nature Communications* 2019;10:1–8. <https://doi.org/10.1038/s41467-019-11311-9>.
397
398 [3] Nightingale Health UK Biobank Initiative, Julkunen H, Cichońska A, Slagboom PE, Würtz
399 P. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and
400 COVID-19 in the general population. *ELife* 2021;10:e63033.
401 <https://doi.org/10.7554/eLife.63033>.
402 [4] Buergel T, Steinfeldt J, Ruyoga G, Pietzner M, Bizzarri D, Vojinovic D, et al. Metabolomic
403 profiles predict individual multidisease outcomes. *Nat Med* 2022;28:2309–20.
404 <https://doi.org/10.1038/s41591-022-01980-3>.
405 [5] Group NHBC, Barrett JC, Esko T, Fischer K, Jostins-Dean L, Jousilahti P, et al. Metabolomic
406 and genomic prediction of common diseases in 477,706 participants in three national
407 biobanks 2023:2023.06.09.23291213. <https://doi.org/10.1101/2023.06.09.23291213>.
408 [6] Bizzarri D, Reinders MJT, Beekman M, Slagboom PE, Bbmri-nl, van den Akker EB. 1H-
409 NMR metabolomics-based surrogates to impute common clinical risk factors and endpoints.
410 *EBioMedicine* 2022;75:103764. <https://doi.org/10.1016/j.ebiom.2021.103764>.

- 411 [7] Bharti SK, Roy R. Quantitative ¹H NMR spectroscopy. *TrAC Trends in Analytical*
412 *Chemistry* 2012;35:5–26. <https://doi.org/10.1016/j.trac.2012.02.007>.
- 413 [8] Yu B, Zanetti KA, Temprosa M, Albanes D, Appel N, Barrera CB, et al. The Consortium of
414 *Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studies. Am J*
415 *Epidemiol* 2019;188:991–1012. <https://doi.org/10.1093/aje/kwz028>.
- 416 [9] Singh T, Kurki MI, Curtis D, Purcell SM, Crooks L, McRae J, et al. Rare loss-of-function
417 variants in SETD1A are associated with schizophrenia and developmental disorders. *Nat*
418 *Neurosci* 2016;19:571–7. <https://doi.org/10.1038/nn.4267>.
- 419 [10] Julkunen H, Cichońska A, Tiainen M, Koskela H, Nybo K, Mäkelä V, et al. Atlas of plasma
420 NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank. *Nat*
421 *Commun* 2023;14:604. <https://doi.org/10.1038/s41467-023-36231-7>.
- 422 [11] Schoenmaker M, de Craen AJM, de Meijer PHEM, Beekman M, Blauw GJ, Slagboom PE,
423 et al. Evidence of genetic enrichment for exceptional survival using a family approach: the
424 *Leiden Longevity Study. European Journal of Human Genetics* 2006;14:79–84.
425 <https://doi.org/10.1038/sj.ejhg.5201508>.
- 426 [12] van den Akker Erik B., Trompet Stella, Barkey Wolf Jurriaan J.H., Beekman Marian,
427 Suchiman H. Eka D., Deelen Joris, et al. Metabolic Age Based on the BBMRI-NL ¹H-NMR
428 *Metabolomics Repository as Biomarker of Age-related Disease. Circulation: Genomic and*
429 *Precision Medicine* n.d.;0. <https://doi.org/10.1161/CIRCGEN.119.002610>.
- 430 [13] Bizzarri D, Reinders MJT, Beekman M, Slagboom PE, van den Akker EB. MiMIR: R-shiny
431 application to infer risk factors and endpoints from Nightingale Health’s ¹H-NMR
432 metabolomics data. *Bioinformatics* 2022;38:3847–9.
433 <https://doi.org/10.1093/bioinformatics/btac388>.
- 434 [14] Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol*
435 2013;14:R115. <https://doi.org/10.1186/gb-2013-14-10-r115>.
- 436 [15] Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, et al. DNA methylation GrimAge
437 strongly predicts lifespan and healthspan. *Aging (Albany NY)* 2019;11:303–27.
438 <https://doi.org/10.18632/aging.101684>.
- 439